Sarah Cannon Research Institute at Tennessee Oncology

TriStar Centennial Medical Center

Nashville, TN

Sorting 4 by

Not yet accepting

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1
  • Myeloma Service

Accepting patients

Cemsidomide (CFT7455)

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more
  • IKZF1/3
  • Phase 1/2
  • Myeloma Service
  • 21-301

Accepting patients

MMSET Inhibitor

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Learn more
  • Phase 1
  • Myeloma Service
  • 23-222

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Myeloma Service
  • 23-182